New hope for myeloma patients: switching to ixazomib after failed treatments?
NCT ID NCT05013190
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 72 adults with multiple myeloma who switch from a bortezomib- or carfilzomib-based treatment to an ixazomib-based regimen. Researchers are tracking side effects and how long patients go without the disease getting worse. The goal is to see if this switch is a good option in real-world settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ixazomib (NINLARO®)
What this could lead to
If successful, this study could show that switching to ixazomib is a safe and effective option for multiple myeloma patients who have already tried bortezomib or carfilzomib.
What could go wrong
This is an observational study, not a controlled trial, so results may not prove cause and effect. It is also small (72 participants) and focused on Chinese patients, so findings may not apply to other populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, 010050, China
-
Anhui Cancer Hospital
Hefei, Anhui, 230000, China
-
Beijing Chao-Yang Hospital,Capital Medical University
Beijing, Beijing Municipality, 100020, China
-
Beijing Jishuitan Hospital
Beijing, Beijing Municipality, 100096, China
-
Henan Province People Hospital
Zhengzhou, Henan, 450004, China
-
Qingdao Municipal Hospital
Qingdao, Qingdao, 266071, China
-
Shengjing Hospital affiliated to China Medical University
Shenyang, Liaoning, 110022, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006, China
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
-
The First Affiliated Hospital of Zhenzhou University
Zhengzhou, Henan, 450052, China
-
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300052, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610000, China